The granulomatous disease-vitamin D paradox is clinically important — in sarcoidosis, tuberculosis, and some lymphomas, activated macrophages within granulomata express 1-alpha-hydroxylase enzyme autonomously (independent of renal regulation by PTH and calcium), converting 25-OH-D to the active 1,25-OH-D. This autonomous production causes hypercalcaemia and hypercalciuria even when serum 25-OH-D is low or normal. In these conditions, vitamin D supplementation is potentially dangerous — increasing the substrate (25-OH-D) available for autonomous conversion by macrophages will worsen the hypercalcaemia. The practical implication: before prescribing vitamin D replacement for low 25-OH-D, check adjusted calcium. If calcium is elevated in the context of low 25-OH-D: measure 1,25-OH-D (likely elevated), ACE level, CXR, and refer to gastroenterology or respiratory/rheumatology before supplementation. The normal rule is: low 25-OH-D + high PTH + low-normal calcium = simple deficiency requiring supplementation. Low 25-OH-D + suppressed PTH + high calcium = granulomatous disease until proved otherwise.

The UK vitamin D paradox: despite being an island with a relatively mild climate, the UK has extremely high rates of vitamin D deficiency — because at UK latitude (50-59 degrees North), UV-B radiation between October and April is insufficient to stimulate cutaneous vitamin D synthesis even on a sunny day. The sun's angle is too low for the UV-B wavelengths (280-315 nm) to penetrate the atmosphere sufficiently. This means that vitamin D synthesised during the summer months must be stored in adipose tissue and liver to last through the winter. People with dark skin, who have higher melanin concentrations reducing UV-B penetration, cannot synthesise adequate vitamin D even in UK summer sunlight — requiring approximately 3-6 times longer sun exposure than pale-skinned individuals to produce the same amount of vitamin D. This explains why South Asian, Black African, and Black Caribbean populations in the UK have dramatically higher rates of vitamin D deficiency than white populations living in the same geographic area. SACN (Scientific Advisory Committee on Nutrition) 2016 report established the current UK recommendation: all adults and children over 1 year should take 10 mcg (400 IU) vitamin D daily throughout the year, with higher doses for those at highest risk.

The bisphosphonate-vitamin D deficiency interaction is a critical prescribing safety point — oral bisphosphonates (alendronic acid, risedronate) bind to and inhibit osteoclast activity, reducing bone resorption. In a vitamin D-deficient patient, calcium absorption from the gut is already reduced (due to low 1,25-OH-D). When bisphosphonate further reduces bone resorption (the secondary source of calcium for maintaining serum calcium), severe hypocalcaemia can result. Cases of severe hypocalcaemia, tetany, and seizures have been reported after bisphosphonate initiation in vitamin D-deficient patients. The safe practice: always check 25-OH-D (and calcium) before initiating bisphosphonate for osteoporosis. If 25-OH-D is below 50 nmol/L: complete a loading regimen and confirm vitamin D and calcium have normalised before starting the bisphosphonate. This is not a reason to delay starting treatment indefinitely — loading takes 8-12 weeks — but the deficiency must be corrected first.

Antiepileptic drug-vitamin D interaction is one of the most clinically significant and underappreciated drug-nutrient interactions — enzyme-inducing antiepileptics (carbamazepine, phenytoin, phenobarbitone, primidone) are potent inducers of CYP3A4 and CYP2C9 hepatic enzymes, which accelerate the catabolism of 25-OH-D to inactive metabolites, causing vitamin D deficiency and secondary hyperparathyroidism even in patients with adequate sunlight exposure and dietary vitamin D. The clinical consequences: reduced bone mineral density, increased fracture risk (approximately 2-3x higher in patients on enzyme-inducing antiepileptics), and osteomalacia in severe deficiency. All patients on long-term enzyme-inducing antiepileptics should: have annual 25-OH-D testing, be supplemented with at least 800-2000 IU/day vitamin D (higher doses may be needed), and receive DEXA scanning every 2-3 years. The newer non-enzyme-inducing antiepileptics (levetiracetam, lamotrigine at standard doses, gabapentin) do not have this effect and are preferred for patients with pre-existing osteoporosis or vitamin D deficiency.

The practical vitamin D prescribing distinction between cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) matters — D3 (cholecalciferol) is the natural form synthesised in human skin and is approximately 1.7x more potent at raising serum 25-OH-D than the equivalent dose of D2 (ergocalciferol), which is the plant-derived form. UK NHS prescribing predominantly uses D3 (Invita D3, Fultium D3, Aviticol) for treatment and D3-containing supplements (Adcal-D3, Calcichew D3) for combined calcium and vitamin D supplementation in osteoporosis. The weekly high-dose preparations (Invita D3 25,000 IU weekly or 50,000 IU monthly) are particularly useful for loading regimens and for patients with malabsorption who cannot achieve adequate levels with daily supplements. GPs should prescribe by dose in IU or mcg (not by brand) to allow pharmacist substitution with equivalent products.

The loading dose rationale: vitamin D is fat-soluble and has a half-life of approximately 4-6 weeks in blood, but the body stores are in adipose tissue and liver, with a much longer effective duration. A loading regimen rapidly repletes tissue stores and achieves therapeutic serum levels within 2-4 weeks, whereas daily low-dose supplementation alone in a severely deficient patient would take 3-6 months to normalise. The total loading dose of 300,000 IU (approximately 7.5 mg) is well within safety margins — toxicity requires sustained doses above 10,000 IU/day for many months. The practical prescribing choices for loading: (1) weekly 50,000 IU sachets (Invita D3 — dissolve in water) for 6 weeks = 300,000 IU total — good compliance; (2) daily 4,000 IU for 12 weeks = 336,000 IU total — suits patients who prefer daily routine; (3) single very-high-dose injections (300,000 IU IM) — useful for patients with confirmed malabsorption or poor compliance with oral therapy.

Healthy Start vitamins are a significant health equity intervention that GPs should actively promote — they are available free to: pregnant women who receive qualifying benefits, mothers with children under 4 who receive qualifying benefits, and pregnant women under 18 (regardless of benefits status). The vitamins contain 400 mcg folic acid + 70 mg vitamin C + 340 IU vitamin D — addressing three key nutritional deficiencies in at-risk populations simultaneously. Despite being free, uptake is poor — approximately 50-60% of eligible women do not receive them, most commonly because healthcare professionals do not mention them at antenatal appointments. GPs and midwives should mention Healthy Start vitamins at every first antenatal appointment with eligible women. The Healthy Start scheme also provides vouchers for fresh fruit, vegetables, pulses, and plain cow's milk for eligible families — GPs can signpost to Healthy Start (www.healthystart.nhs.uk) for application.

The vitamin D and falls prevention evidence base is one of the strongest cases for supplementation in the elderly — a Cochrane review (Gillespie et al. 2012) showed that vitamin D supplementation reduces falls in older people by approximately 19% when given with calcium. The mechanism: vitamin D has direct effects on muscle function (VDR in skeletal muscle regulate contractile protein synthesis), improving muscle strength and balance, which translates into fewer falls. NICE NG147 (Falls prevention, 2019) specifically recommends vitamin D assessment and supplementation as part of the multifactorial falls prevention intervention. In elderly patients at high falls risk, vitamin D supplementation (800-1,000 IU OD) with or without calcium should be initiated as a routine falls prevention measure, regardless of whether a baseline 25-OH-D has been measured, given the near-universal deficiency in this population.

The proximal myopathy-vitamin D connection is frequently missed in clinical practice because vitamin D deficiency-related myopathy mimics many common conditions (functional weakness, deconditioning, polymyalgia rheumatica, fibromyalgia). The characteristic features that point to vitamin D deficiency: difficulty rising from a chair without using arms, difficulty climbing stairs, waddling gait, and symmetrical proximal limb weakness with normal or only mildly elevated CK. Unlike inflammatory myopathy, there is no significant tenderness, fever, or systemic features. The diagnosis is confirmed by: 25-OH-D below 25 nmol/L + elevated ALP (high bone turnover) + low-normal phosphate + secondary hyperparathyroidism. Treatment response is dramatic — strength and pain typically improve within 4-6 weeks of high-dose supplementation, long before biochemical normalisation is complete. This rapid clinical improvement is a useful diagnostic confirmation.